Kala Entered into Definitive Agreement with Alcon to Acquire Eysuvis and Inveltys for the Treatment of Acute Dry Eye Disease
Shots:
- Kala will receive $60M up front along with additional fees upon achievement of commercial-based sales milestones. The transaction is expected to close in Q3’22
- The acquisition will complement Alcon’s portfolio & systane line of eye drops used for the ongoing management of dry eye symptoms. Kala intends to focus on developing KPI-012 for sev. ocular diseases & will initiate a P-II/III trial of KPI-012 for PCED in Q4’22 along with expanding its development program with additional details
- Eysuvis is the 1st US FDA-approved therapy for short-term (~2wks.) treatment of DED. Alcon will also acquire Inveltys, a corticosteroid for BID treatment of post-operative inflammation & pain following ocular surgery
Ref: Businesswire| Image: Kala
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
